A limitation of the study was that there was no information on molecular biomarkers for GBM, including O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation and isocitrate dehydrogenase 1 (IDH1) gene mutation. This evidence concerns the gene IDH1 and glioblastoma.